USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
REGENX BIOSCIENCES, LLC
Address:
750 17TH ST NW, STE 1100
WASHINGTON, DC 20006-
Phone:
N/A
URL:
N/A
EIN:
126414796
DUNS:
829689608
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $829,025.00 3
STTR Phase I $211,009.00 1

Award List:

Scalable Production of New Generation Adeno-Associated Virus Gene Therapy Vectors

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$263,277.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this application is to develop a scalable production system for the manufacture of an adeno- associated virus (AAV) serotype 8-based gene therapy vector bearing a human low density lipoprotein recept or (hLDLR) transgene for the treatment of… More

AAV Mediated Gene Transfer to the CNS for MPS I

Award Year / Program / Phase:
2012 / STTR / Phase I
Award Amount:
$211,009.00
Agency:
HHS
Principal Investigator:
Karen Kozarsky – 202-577-4374
Research Institution:
UNIVERSITY OF MINNESOTA
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Mucopolysaccharidosis type I (MPS I) is an autosomal recessive storage disease caused by the absence of a-L-iduronidase (IDUA), resulting in systemic accumulation of glycosaminoglycan (GAG) storage materials, hepatosplenomegaly, skeletal dysplasias,… More

Novel Adeno-Associated Viral Therapy for Wet Age-Related Macular Degeneration

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$304,421.00
Agency:
HHS
Principal Investigator:
Karen Kozarsky – 202-577-4374
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this project is to develop a novel gene-based delivery system to treat neovascular age- related macular degeneration (wet AMD), a debilitating ocular disease. AMD is the leading cause of blindness inAmericans over 60 years of age, with wet AMD… More

Genetically-delivered Bevacizumab for Treatment of Wet Age-Related Macular Degene

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$261,327.00
Agency:
HHS
Principal Investigator:
Karen Kozarsky – 202-577-4374
Abstract:
DESCRIPTION (provided by applicant): The goal of this Phase I SBIR is the pre-clinical development of a novel gene-based delivery system for bevacizumab (anti-VEGF antibody) to treat wet age-related macular degeneration (AMD). The premise is based on: (1)the demonstrated efficacy of monthly… More